Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia
Matthew S. Davids, Claire Telford, Sarang Abhyankar, Catherine Waweru, Ingo Ringshausen
Abstract
< 0.05) for acalabrutinib (with or without obinutuzumab) versus venetoclax plus obinutuzumab. There was no statistically significant difference in progression-free survival between acalabrutinib (with or without obinutuzumab) and any of the comparators. This MAIC demonstrated a favorable safety profile for acalabrutinib-based therapy compared with other targeted therapies in treatment-naïve patients with CLL, without compromising efficacy.
Topics & Concepts
ObinutuzumabMedicineIbrutinibChronic lymphocytic leukemiaNeutropeniaInternal medicinePharmacologyOncologyLeukemiaChemotherapyChronic Lymphocytic Leukemia ResearchGastrointestinal Tumor Research and TreatmentLymphoma Diagnosis and Treatment